Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

American Journal of Cardiology

Volumn 82, Issue 1, 1998, Pages 61-65

  Hoerger, Thomas J ^a   Bala, Mohan V ^b   Bray, Jeremy W ^b   Wilcosky, Timothy C ^b   LaRosa, John ^b  

^a RTI INTERNATIONAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGED; CHOLESTEROL, LDL; FEMALE; HEALTH SURVEYS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PREVALENCE; SEX DISTRIBUTION; UNITED STATES;

EID: 0032127864     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00227-6     Document Type: Article

References (16)

1. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. (Vital and health statistics, plan and operation of the third national health and nutrition examination survey, 1988-1994). (DHHS publication no. (PHS) 94-1308, series 1, No. 32 4-0485).
2. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA. 269:1993;3015-3023.
3. SAS Institute Inc Statistical Software . 1993;SAS Institute Inc, Cary, NC.
4. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., Mäenpää H., Mälkönen M., Mänttäri M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjöblom T., Nikkilä E.A. Helsinki heart study primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia - safety of treatment, changes in risk factors, and incidence of coronary heart disease . N Engl J Med. 317:1987;1237-1245.
5. The lipid research clinics coronary primary prevention trial - results of 6 years of post-trial follow-up. Arch Intern Med. 152:1992;1399-1410.
6. Haheim L.L., Holme I., Hjermann I., Leren P. The predictability of risk factors with respect to incidence and mortality of myocardial infarction and total mortality. A 12-year follow-up of the Oslo Study, Norway. J Intern Med. 234:1993;17-24.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian simvastatin survival study (4S) . Lancet. 344:1994;1383-1389.
8. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia West of Scotland Coronary Prevention Study Group . N Engl J Med. 333:1995;1301-1307.
9. Hunninghake D.B., Stein E.A., Dujovne C.A., Harris W.S., Feldman E.B., Miller V.T., Tobert J.A., Laskarzewski P.M., Quiter E., Held J., Taylor A.M., Hopper S., Leonard S.B., Brewer B.K. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med. 328:1993;1214-1219.
10. Denke M.A. Cholesterol-lowering diets a review of the evidence . Arch Intern Med. 155:1995;17-26.
11. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cholesterol Education Program. Cholesterol lowering in the patient with coronary heart disease: physician monography. September 1997. (NIH Publication no. 97-3794).
12. Schectman G., Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease factors limiting achievement of lipid goals . Am J Med. 100:1996;197-204.
13. Kellick K.A., Burns K., McAndrew E., Haberl E., Hook N., Ellis A. Outcome monitoring of fluvastatin in a department of veterans affairs lipid clinic. Am J Cardiol. 76:1995;62A-64A.
14. Marcelino J.J., Feingold K.R. Inadequate treatment with 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors by health care providers. Am J Med. 100:1996;605-610.
15. Pasternak R.C., Brown L.E., Stone P.H., Silverman D.I., Gibson C.M., Sacks F.M. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. Ann Intern Med. 125:1996;529-540.
16. Pearson T., Laurora I.M. Treatment success in the lipid treatment assessment project (L-TAP). Circulation. 96:1997;361.